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Abstract
Background: Growth, differentiation and regional specification of telencephalic domains, such as
the cerebral cortex, are regulated by the interplay of secreted proteins produced by patterning
centers and signal transduction systems deployed in the surrounding neuroepithelium. Among
other signaling molecules, members of the fibroblast growth factor (FGF) family have a prominent
role in regulating growth, differentiation and regional specification. In the mouse telencephalon the
rostral patterning center expresses members of the Fgf family (Fgf8, Fgf15, Fgf17, Fgf18). FGF8 and
FGF17 signaling have major roles in specification and morphogenesis of the rostroventral
telencephalon, whereas the functions of FGF15 and FGF18 in the rostral patterning center have not
been established.
Results: Using Fgf15-/- mutant mice, we provide evidence that FGF15 suppresses proliferation, and
that it promotes differentiation, expression of CoupTF1 and caudoventral fate; thus, reducing Fgf15
and Fgf8 dosage have opposite effects. Furthermore, we show that FGF15 and FGF8 differentially
phosphorylate ERK (p42/44), AKT and S6 in cultures of embryonic cortex. Finally, we show that
FGF15 inhibits proliferation in cortical cultures.
Conclusion:  FGF15 and FGF8 have distinct signaling properties, and opposite effects on
neocortical patterning and differentiation; FGF15 promotes CoupTF1  expression, represses
proliferation and promotes neural differentiation.
Background
Regional specification, growth and differentiation of tel-
encephalic subdivisions, such as the cerebral cortex, are
regulated by the interplay of secreted proteins produced
by patterning centers and signal transduction systems
deployed in the surrounding neuroepithelium. The dorsal
telencephalic patterning center is the source for bone mor-
phogenetic proteins (BMPs) and Wnts that regulate devel-
opment of dorsal and caudal parts of the telencephalon,
including the choroid plexus and hippocampus [1-3]. A
putative ventral patterning center expresses sonic hedge-
hog (SHH); dorsoventral patterning of the telencephalon
is controlled through the GLI3 repressor of the SHH path-
way [4-6]. An additional putative patterning center at the
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cortical-subcortical junction (pallium-subpallium bound-
ary (PSB)) expresses multiple signaling molecules, such as
Tgfα, Neuregulin 1 and 3, Fgf7, the putative Wnt antagonist
Sfrp2 [7,8] and Fgf15 (this paper). Finally, the rostral pat-
terning center expresses members of the Fgf family (Fgf8,
Fgf15, Fgf17, Fgf18) [9-13].
The mammalian fibroblast growth factor (FGF) family
consists at least 22 members whose functions range from
specifying regional and cell fate to promoting prolifera-
tion, differentiation and survival [14]. FGF ligand binding
to their cognate tyrosine kinase receptors (FGFR1-4) acti-
vates two major phosphorylation cascades: the Ras/
mitogen activated protein kinase (MAPK) and the phos-
phatidylinositol 3-kinase/AKT pathways [14].
FGF signaling is implicated in early steps of neural induc-
tion [14]. As the neural plate matures, its rostral margin,
known as the anterior neural ridge, expresses at least three
members of the Fgf family, Fgf8, Fgf17 and Fgf18 [9-12].
Following neurulation, these genes continue to be
expressed in the rostral midline of the forebrain. Fgf15
expression is also prominent in the early rostral forebrain
[15-17]. Within the rostral patterning center, Fgf8  and
Fgf18 are expressed in its core, whereas Fgf17 expression
extends dorsally [18] and Fgf15  extends ventrally
[13,16,17,19]. Fgf15 is also expressed at the PSB and in
the caudal-most region of the ventral pallium
[16,17,19,20].
FGF8 and FGF17 signaling have major roles in specifica-
tion and morphogenesis of the rostroventral telen-
cephalon. Within the cortex, FGF8 is essential for
producing most of the frontal cortex [17,21,22], whereas
FGF17 is essential for the development of the dorsome-
dial frontal cortex [17,18]. The functions of FGF15 and
FGF18 in the rostral patterning center have not been
established, although Fgf18  expression in the cortical
plate is implicated in laminar patterning and neuronal
migration [23].
FGF8 promotes proliferation and survival of telencephalic
progenitor cells, and specifies rostral telencephalic fate
through positively regulating expression of several tran-
scription factors, including Erm, Er81, Foxg1, Nkx2.1, Pea3
and Sp8 [16,17,19,22,24,25]. In addition, FGF8 represses
caudal telencephalic fate through reducing the expression
of  CoupTF1,  Emx2  and  Wnt8b  [12,21,22,25-27].  Fgf17
expression is genetically downstream of Fgf8 (this paper)
and it is important in local patterning within the rostral
cortex [17,18].
FGF8, FGF17 and FGF18 belong to the same subfamily
based on their amino acid sequence, whereas FGF15,
known as FGF19 in humans, chickens and zebrafish, is
part of a distinct subfamily [28,29].
Here we explore the functions of FGF15 in neocortical
development. Previous loss of function studies in the
mouse established its function in the development of the
gall bladder, inner ear, and cardiac outflow tract [30-33].
The function of the zebrafish Fgf15 homologue (Fgf19)
has been assessed in the developing brain using antisense
(morpholino) oligonucleotides [34]. That study provided
evidence that Fgf15(19) promotes proliferation, similar to
known functions of other Fgfs. On the other hand, our
analysis of Fgf15-/- mutant mice, and primary cortical cul-
tures treated with recombinant FGF15, provides evidence
that FGF15 suppresses proliferation and promotes differ-
entiation in the developing telencephalon. Furthermore,
we demonstrate that Fgf15  promotes expression of
CoupTF1, a transcription factor that represses prolifera-
tion, and promotes differentiation and caudoventral fate.
Thus, in vivo reduction of Fgf15 dosage has the opposite
effect of reducing Fgf8 dosage. Finally, in primary cortical
cultures, we demonstrate that FGF15 and FGF8 have dis-
tinct effects on phosphorylation of ERK (p42/44), AKT,
and S6, providing a link between signaling differences and
the distinct cellular effects of these proteins.
Results
Fgf15 expression is repressed by FGF8 and is promoted by 
SHH
To assess the role of FGF15 in cortex development, we
extended the analysis of Fgf15 expression in the develop-
ing telencephalon by in situ RNA hybridization, to com-
plement previous reports [16,17,19]. At embryonic day
9.5 (E9.5), Fgf15 was expressed in the anterior forebrain
neuroepithelium (Figure 1a), but was excluded from the
anterior dorsal midline where Fgf8 was expressed (Figure
1a, b, arrowhead). At E12.5, Fgf15 was strongly expressed
in the septum (Additional file 1g, arrow), preoptic area
(Additional file 1h, arrow), and weakly expressed in the
neuroepithelium of the PSB (Additional file 1g, arrow-
head). In addition, Fgf15 was strongly expressed in the
caudal ganglionic eminence (CGE; Additional file 1j,
arrow).
The overlapping and complementary expression of Fgf15
and Fgf8 in the dorsal midline suggests regulatory interac-
tions between these factors. Gain-of-function experiments
by Gimeno and Martinez [16] demonstrated that FGF8
protein can induce Fgf15  expression in the mesen-
cephalon and prosencephalon. Thus, we analyzed the
expression of Fgf15 in severely hypomorphic Fgf8 mutants
(Fgf8Null/Neo) [22]. At E9.5, Fgf15 expression was strongly
reduced at the midbrain/hindbrain boundary (Figure 1c,
d, arrows), consistent with Gimeno and Martinez [16].
However, in the rostral forebrain, Fgf15  expressionNeural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
Page 3 of 18
(page number not for citation purposes)
remained strong, and it was ectopically expressed in the
anterior midline (Figure 1c, d, c', d', arrowheads). At
E12.5, Fgf15 expression remained strong in the dysmor-
phic septal area and appeared to be increased in the CGE
(Additional file 1e–j'). Thus, while Fgf15 is positively reg-
ulated by FGF8 in the midbrain, it is repressed by FGF8 in
the prosencephalic midline.
There is evidence that SHH promotes Fgf15 expression in
the diencephalon [35] and in the cortex [6,20]. Our anal-
ysis of the Shh-/- mutant extended these findings by dem-
onstrating that Fgf15  expression in the rostral
telencephalon requires SHH function (Additional file 2).
Thus, while Fgf15 expression in the rostral telencephalon
requires SHH, it remains strong in the severe Fgf8 hypo-
morph, despite the lack of telencephalic Shh expression in
these mutants [22]. In addition, Gli3, a repressor of the
SHH signal, may to be over-expressed in the Fgf15
mutants at E12.5 (Additional file 2q, q'), suggesting a pos-
itive feedback between FGF15 and SHH.
Opposite effects of FGF15 and FGF8 on patterning gene 
expression in the cortical primordium
To determine FGF15's functions in forebrain develop-
ment we analyzed the Fgf15 null (Fgf15-/-) mutant mouse
[32], and focused on the cortical phenotype. Histological
analysis showed that the mutant cortex was thinner than
the wild type (Figures 2 and 3; quantification below). The
gross morphology of Fgf15 mutant embryos is similar to
the wild-type cohort (Additional file 3).
We started the analysis at E9.5, soon after neurulation has
generated the telencephalic vesicles, by studying mRNA
expression of genes known to have important roles in cor-
tical development or known to be markers of FGF signal-
ing.
CouTF1 promotes caudoventral cortical identity [36-38].
While reducing Fgf8 dosage increased CoupTF1 expression
[21,22], we observed that loss of Fgf15 strongly reduced
its expression at E9.5 (Figure 1e, f). Subtle changes in
expression are also observed, including increased Fgf8
expression (Figure 1g, h); however, establishing these
changes would require more quantitative methods. On
the contrary, we did not observe a major effect on the
expression of two genes that are positively regulated by
FGF signaling, Spry2 (Figure 1i, j) and Erm (Figure 1k, l).
Expression of cMyc, a gene downstream of the Ras/MAPK
signaling [39,40], may be slightly increased (Figure 1m,
n).
Next, we interrogated FGF15 function by analyzing
CoupTF1, Mest, Sp8, Pax6, Emx2 and Erm expression in the
cortical ventricular and mantle zones at E12.5 and E14.5.
As at E9.5, CoupTF1 expression was strongly reduced (Fig-
In situ RNA hybridization on horizontal sections in wild-type,  Fgf8Null/Neo and Fgf15-/- E9.5 embryos Figure 1
In situRNA hybridization on horizontal sections in 
wild-type,Fgf8Null/Neoand Fgf15-/-E9.5 embryos. (a, b) 
Fgf15 (a) and Fgf8 (b) expression in adjacent sections of a 
wild-type embryo. (c-d') Fgf15 expression in wild-type (c) and 
Fgf8Null/Neo embryos (d). Higher magnifications of (c, d) are 
shown in (c', d'). (e-n) Expression analysis in wild-type and 
Fgf15 mutant embryos showing adjacent sections of CoupTF1 
(e, f), Fgf8 (g, h), Spry2 (i, j), Erm (k, l) and cMyc (m, n). 
Arrowheads in (a, b): rostral midline that is Fgf8+ and Fgf15-; 
the midline becomes Fgf15+ in Fgf8Null/Neo (d, d'). Arrow in (d): 
loss of Fgf15 expression in the midbrain of the Fgf8Null/Neo 
mutant. Arrows in (e, f): reduced CoupTF1in Fgf15-/-. Bar in 
(a) is 200 μm.Neural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
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Analysis of the cortical patterning defects in the Fgf15 mutants Figure 2
Analysis of the cortical patterning defects in the Fgf15 mutants. (a-r) In situ RNA hybridization on coronal sections of 
Fgf15+/+ (left column) and Fgf15-/- (right column) embryos at E12.5 (a-l) and E14.5 (m-r). CoupTF1 (a, b, m, n), Mest (c, d), Sp8 (e, 
f), Pax6 (g, h), Emx2 (i, j, o, p) and Erm (k, l, q, r). Arrows highlight the changes in the extent and/or intensity of expression. Bar 
in (a, m) is 200 μm.Neural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
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ure 2a, b and 2m, n), in contrast with its increase in Fgf8
mutants [21,22]. Fgf15 and Fgf8 mutants also showed the
opposite effects on Mest and Sp8 expression (Figure 2c, d
and 2e, f, respectively) [22,41].
On the other hand, Pax6, Erm and Emx2 showed subtle
changes in the Fgf15  mutant.  Pax6  cortical ventricular
zone expression showed a modest decrease at E12.5 (Fig-
ure 2g, h) as well as Erm at E12.5 and E14.5 (Figure 2k, l
and 2q, r). Emx2 expression may be increased in the dor-
somedial cortical ventricular zone at E12.5 and E14.5
(Figure 2i, j and 2o, p). At this stage Fgf15 expression in
the rostral patterning center does not appear to overlap
with the cortical expression of the gene analyzed here. The
changes in cortical expression could, however, result from
the earlier patterning changes observed at E9.5 (Figure 1)
and through diffusion of FGF15.
Zebrafish treated with morpholinos to Fgf19 (the name of
zebrafish Fgf15) exhibit loss of subpallial molecular fea-
tures [34]. We, however, did not detect a strong subpallial
phenotype in the mouse Fgf15 mutant, although there
was a suggestion of reduced GAD67,Nkx2.1  and  Pax6
expression in the mantle zone of the ventral septum and
piriform cortex (Additional file 4). There was, however, a
clear reduction in the number of GAD67+cortical
interneurons in the dorsomedial cortex (Additional file
4a, b). Reelin expression in this region appeared normal
showing that differentiation of the marginal zone was not
grossly disrupted (Additional file 4e, f).
In summary, reduced expression of Fgf15 and Fgf8 has
opposite effects on the expression of several transcription
factors that have prominent functions in regulating corti-
cal regional fate, proliferation and differentiation. This
was particularly clear for CoupTF1, which promotes cau-
doventral cortical fate [37,38], and which represses prolif-
eration and promotes differentiation [38].
FGF15 promotes maturation of the cortical neural 
precursors in the ventricular and subventricular zones
The cortex in the Fgf15 mutants was thinner than the wild
type at E14.5 (Figures 2 and 3), suggesting that FGF15
may regulate the balance between proliferation and differ-
entiation. To explore this, we analyzed markers of differ-
entiation and indices of proliferation.
Neurogenin2 (Ngn2) expression marks progenitor cells in
the cortical ventricular zone (VZ) and subventricular zone
(SVZ) and is largely excluded from the postmitotic neu-
rons of the cortical plate [42] (Figure 3a). Fgf15 mutants
maintained strong Ngn2 expression in the VZ, while its
expression in the SVZ seemed to be reduced; however, the
Ngn2 negative area was much thinner (Figure 3a, b), sug-
gesting reduced cortical plate thickness. To confirm this
observation, we studied expression of β-III-Tubulin, a
marker of differentiating neurons. Indeed, the width of
the cortical postmitotic zone was greatly reduced in the
Fgf15 mutant (50% in ventral regions and 45% in dorsal
regions; Figure 3c, d), while the width of the VZ was larger
in the mutants (30% in ventral regions and 25% in dorsal
regions; Figure 3c, d). The reduced thickness of the cortical
plate was confirmed by analyzing expression of markers
of early born cortical projection neurons, Tbr1 and Mef2C
Analysis of the cortical neurogenesis defects in the Fgf15  mutants Figure 3
Analysis of the cortical neurogenesis defects in the 
Fgf15 mutants. (a-h) In situ RNA hybridization (a, b, e-h) 
and immunofluorescence (c, d) on coronal sections of Fgf15+/
+ (left column) and Fgf15-/- (right column) embryos at E14.5. 
Ngn2 (a, b), β-III-Tubulin (c, d), Tbr1 (e, f), Mef2C (g, h). 
Arrows point out the reduced thickness of the cortical plate 
expression of Tbr1 and Mef2C. Brackets in (a-d) highlight the 
reduced thickness of the cortical plate. CP, cortical plate; 
SVZ, subventricular zone; VZ, ventricular zone. Bar in (a) is 
200 μm.Neural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
Page 6 of 18
(page number not for citation purposes)
(Figure 3e–h). Tbr1 and Mef2C expressions were reduced
in the cortical plate of the Fgf15 mutants (Figure 3e, f, g,
h). Thus, Fgf15 mutants show a defect in the growth of the
cortical plate, perhaps due to defect in neurogenesis.
We explored the hypothesis that the cortical plate defect is
caused because FGF15 may promote the switch between
proliferation and differentiation. Thus, we assessed the
mitotic index by immunostaining with phospho-histone
H3 (PH3), a marker for M phase of the cell cycle. At E14.5,
we observed a 37% increase in the density of PH3+ cells in
the cortical VZ and a 42% increase in the SVZ (Figure 4a–
c). This was already evident at E12.5 when the increase
was 20% (Additional file 5a–c).
The rate of proliferation of the cortical precursor cells is
linked to the length of the cell cycle; in addition, the frac-
tion of cells in a given phase of the cell cycle is directly
proportional to the length of that specific phase, relative
to the total length of the cell cycle [43,44]. Sequentially
exposing proliferating cells to iodo-deoxyuridine (IdU)
and bromo-deoxyuridine (BrdU) allows one to differenti-
ate between defined populations of proliferating cells and
then to calculate the cell cycle length (see Materials and
methods). We compared the length of the cell cycle in
E12.5 and E14.5 wild type and Fgf15 mutants using IdU/
BrdU double labeling [45] (Figure 4d–f; Additional file
5d–f). Cell cycle length in the mutants was reduced to 11
hours, compared to the 13.5 hours of the wild type at
E14.5 (Figure 4d–f), and 10 hours, compared to the 11
hours of the wild type at E12.5 (Additional file 5d–f).
Next, we analyzed the fraction of neural precursor cells
exiting the cell cycle to become neurons (Q fraction) at
E14.5. To identify cells exiting the cell cycle, we used dif-
ferential labeling by IdU and BrdU [45]. The IdU/BrdU
double labeling method allows one to distinguish
between cells that are proliferating from cells that exit the
cell cycle (see Materials and methods). Fgf15  mutants
showed a 38% reduction in Q fraction (cells exiting the
cell cycle) (Figure 4g–i).
Overall, these data provide evidence that reducing the
dosage of Fgf15 reduces cell cycle length and cell cycle exit.
Thus, FGF15 induces neurogenesis and this observation
contrasts with the typical function of FGFs in promoting
proliferation and maintenance of the neural progenitor
state [14].
Analysis of the Wnt and the retinoic acid signaling 
pathways in the Fgf15 mutants
To investigate how FGF15 regulates cell cycle and neuro-
genesis, we studied signaling pathways that regulate the
switch between proliferation and neurogenesis in Fgf15
mutants. First, we investigated the retinoic acid pathway,
which promotes neural differentiation [46]. We intro-
duced an allele that expresses LacZ under the control of
retinoic acid receptor enhancer elements [47] into the
Fgf15-/-background. At E12.5 and E14.5, there was a
strong decrease in β-galactosidase activity in the mutants
(Figure 5a–d), suggesting reduced retinoic acid signaling,
consistent with the decrease in neuronal differentiation
(Figure 3).
Wnt signaling through the β-catenin pathway promotes
cortical proliferation [2,48-50] and represses differentia-
tion of cortical neural progenitors [51]. We introduced a
Wnt/β-catenin LacZ reporter allele [52] into the Fgf15-/-
mutants and observed increased numbers of β-galactosi-
dase+ cells in their cortex at E12.5 and E14.5 (Figure 5e–
h), consistent with an increase in Wnt signaling, and the
increase in proliferation (Figure 4).
Expression of FGF pathway effector genes in Fgf15 
mutants
Towards understanding the mechanism of FGF15 func-
tion, we examined the effect of Fgf15 mutation on selected
components of the FGF signal transduction pathway in
the rostral telencephalon at E9.5, E12.5 and E14.5. We
focused on expression of Fgf receptors (Fgfrs) and Sprouty2
(Spry2); Sprouty genes encode negative regulators of the
FGF signaling pathway that are induced by FGF8
[24,53,54].
At E9.5 and E12.5, expression of Fgf8 and Spry2 in the ros-
tral patterning center and the rostral midline (that is,
anlage of the septum) appeared normal in the Fgf15
mutants (Figures 1g–j and 6a–l). At later stages, E12.5 and
E14.5, Spry2 expression was reduced in the VZ of the ven-
trolateral cortex (Figure 6e–h, arrows) while its expression
in the dorsomedial cortex was preserved (Figure 6e–f,
arrowheads and Figure 6i–l).
Next we examined expression of Fgfr1-4  at E12.5 and
E14.5. Fgfr2 showed the largest change in expression: it
increased in the VZ, particularly in the dorsolateral cortex
(Additional file 6e–h); in the cortical plates its expression
was lost. Fgfr1 showed subtle changes in the VZ (a slight
increase), but was reduced in the cortical plate and inter-
mediate zone (Additional file 6a–d). Fgfr3 expression was
reduced in the dorsal cortex at E14.5 (Additional file 6i–l,
arrows).
FGF15 preferentially binds to FGFR4 in vitro [33,55-57].
We confirmed that Fgfr4 expression was not detectable in
the E12.5 cortex (data not shown), as previously pub-
lished [58]. However, we did observe its expression in the
superficial cortical plate at E14.5; this expression domain
was preserved, but thinner in the Fgf15 mutants (Addi-
tional file 6m–n). Thus, Fgf15  mutants showed variedNeural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
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Analysis of proliferation and cell cycle in the Fgf15 mutants Figure 4
Analysis of proliferation and cell cycle in the Fgf15 mutants. (a-i) Comparison of the rate of proliferation of the neuro-
nal progenitors at E14.5 in coronal hemisections from Fgf15+/+ (left column) and Fgf15-/- (right column) embryos. The number 
of neuronal progenitors undergoing mitosis was evaluated by PH3+ immunofluorescence (a, b); quantification of the PH3+ cells 
in the VZ and SVZ is shown in (c) (n = 3; p = 0.0019, Student's t-test, indicated by * and **; see Materials and methods). The 
analysis of the cell cycle length (d, e) (quantification in (f)) and of the number of neuronal progenitors exiting the cell cycle (Q 
fraction) (f, g) (quantification in (i)) were performed at E14.5 by double labeling with IdU and BrdU (n = 3; p = 0.001, Student's 
t-test, indicated by *; see Materials and methods). The rectangles in a-b, d-e, g-h indicate the sampled bins. The error bars indi-
cate the standard deviations. MUT, mutant; SVZ, subventricular zone; VZ, ventricular zone; WT, wild type.Neural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
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effects on the expression of several FGF receptors in corti-
cal progenitors and in the cortical plate.
FGF15 and FGF8 differentially affect signaling pathways in 
cultured embryonic cortical cells
Toward establishing how FGF15 and FGF8 differentially
affect cortical patterning proliferation and differentiation,
we studied the effects of recombinant FGF15 and FGF8
proteins on dissociated E12.5 cortex; at this age most of
the cortical cells are neuroepithelial progenitors.
Unlike mouse and human FGF2 and FGF8, which share
93% and 98% amino acid identity, mouse FGF15 shares
only 51% identity with its human homolog FGF19 (data
not shown) [28,29]. Thus, we compared the effect of puri-
fied mouse recombinant FGF15 protein with commer-
cially available recombinant human FGF19 protein. Our
results with FGF15 and FGF19 were indistinguishable
(data not shown).
FGFs signal through two major pathways that when acti-
vated phosphorylate ERK (42/44) and the AKT [14,59].
These pathways can also activate other important kinases
that regulate processes such as protein translation (S6
kinase) and Wnt signaling (GSK3 kinase).
First, we began titrating the FGFs to find concentrations
that led to robust changes in the levels of pERK (42/44).
We compared 5 ng/ml with 50 ng/ml and found that they
led to similar results, with the higher concentration yield-
ing easily detectable levels of pERK (42/44) (Figure 7a, b;
Additional file 7c, d). We chose to focus on 50 ng/ml.
We found several qualitative differences in the response to
FGF8 and FGF15. First, while both ligands induced a rapid
(5 minutes) increase in pERK, their levels decreased more
rapidly in the FGF15-treated samples (Figure 7a, b). We
used recombinant FGF2 as a control, because it is a known
mitogen for cortical progenitors [60,61], and as an activa-
tor of the ERK kinase pathway (Additional file 7). FGF2
showed similar results as FGF8 (Figure 7; Additional file
7).
While both FGF8 and FGF2 induced the phosphorylation
of AKT (pAKT; Figure 7b, and Additional file 7a, respec-
tively), FGF15 did not (Figure 7a). Activation of ERK and
AKT, through phosphorylation, results in the phosphor-
ylation and subsequent inhibition of GSK3 activity
[62,63]. FGF8 and FGF2 increased levels of pGSK3 (Figure
7d, and Additional file 7b, respectively), whereas FGF15
treatment did not increase pGSK3 (Figure 7c). As GSK3 is
an inhibitor of the Wnt/β-catenin pathway [64], these
results suggest that FGF2/8 may repress Wnt signaling
more than FGF15 through this mechanism.
Activation of the Wnt/β-catenin and retinoic acid signaling  pathways in the Fgf15 mutants Figure 5
Activation of the Wnt/β-catenin and retinoic acid sig-
naling pathways in the Fgf15 mutants.(a-d) Retinoic 
acid pathway activation was determined at E12.5 (a, b) and 
E14.5 (c, d) by β-galactosidase staining of coronal sections of 
Fgf15-/-; RL+ embryos (RL, RARE LacZ, retinoic acid reporter). 
(e-h) The Wnt/β-catenin pathway activation was revealed by 
β-galactosidase staining of coronal sections of Fgf15-/-; BG+ 
(BG, BATgal, Wnt/β-catenin reporter) at E12.5 (e, f) and 
E14.5 (g, h). Arrows indicate the regions that show the larg-
est changes in the extent and/or intensity of expression. 
Three separate cases were analyzed for each genotype. Bar 
in (a, c) is 200 μm.Neural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
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FGFs promote protein translation and cell growth through
the mTor/S6 pathway [65,66]. FGF8- and FGF2-treated
cells increased phosphorylation of S6 protein, albeit with
slower kinetics than pERK and pAKT (Figure 7d, and Addi-
tional file 7b, respectively). On the contrary, FGF15 did
not show this increase; in fact, we observed a reduction of
S6 phosphorylation in the first 15 minutes (Figure 7c).
Finally, we compared the effects of FGF15 and FGF8
recombinant proteins on proliferation and differentiation
of cortical progenitors in vitro. We treated primary E12.5
cortical cultures grown in vitro for 24 and 48 hours with
either FGF15 or FGF8. While FGF8 induced an approxi-
mately 1.7-fold increase in the mitotic index (assessed by
comparing the ratio of PH3+/total cells in FGF8-treated
and untreated cortical cultures), FGF15 caused an approx-
imately 0.25-fold reduction in the mitotic index (Figure
7e–j, and quantification in 7k). This result is consistent
with the increased proliferation of the cortical progenitors
we observed in the Fgf15 mutants, and may reflect the dis-
tinct effects of FGF15 on the phosphorylation of ERK (42/
44), AKT, GSK3 and S6. We did not test these cultures for
apoptosis; however, we have not observed a change in the
number of apoptotic cells in the Fgf15 mutants (data not
shown). A more detailed analysis is required to determine
the role of FGF15 on neural progenitor apoptosis.
Discussion
Here we present the first evidence that Fgf15(19), another
Fgf expressed in the rostral patterning center, has telen-
cephalic functions that oppose Fgf8  and  Fgf17. These
dichotomous phenotypes include effects on proliferation
and on the expression of genes regulating the rostro-cau-
dal patterning of the telencephalon. In addition, FGF15
promotes the neuronal differentiation of cortical progen-
itor cells. Therefore, we propose that FGF15 is a secreted
negative modulator of FGF8/17 signaling outputs. Below,
we discuss the ramifications of this property and insights
into the potential mechanisms by which FGF15 regulates
the development of the neocortex and may modulate
FGF8/17 functions.
Roles of FGF15, FGF8 and SHH in establishing and 
maintaining the rostral patterning center
The vertebrate rostral patterning center expresses multiple
Fgf  genes:  3,  8,  15,  17  and  18  [9-14,16,19,67]. It is
Analysis of FGF signaling components in the Fgf15 mutants Figure 6
Analysis of FGF signaling components in the Fgf15 mutants. (a-l) In situ hybridization on coronal sections: Fgf8 at E12.5 
(a, b) and E14.5 (c, d); Spry2 at E12.5 (e, f, i, j) and E14.5 (g, h, k, l). Arrows in (e-h) indicate the change in Spry2 gene expression 
in the lateral pallium; arrowheads in (e, f) indicate the change in the medial pallium. CP: cortical plate; Se: septum. Bars in (e, g, 
i, k) are 200 μm.Neural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
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Activation of the FGF15 and FGF8 downstream cytosolic effectors Figure 7
Activation of the FGF15 and FGF8 downstream cytosolic effectors. Comparison of phosphorylation levels of four 
proteins that are modified in response to FGF15 and FGF8. E12.5 primary cortical cultures were starved for 24 hours and then 
treated with recombinant FGF15 or FGF8. Cell lysates were analyzed after 0, 5, 15, 30 and 60 minutes by immunoblottingblot-
ting to detect phosphorylated forms of pERK 42/44 (a, b, top panels), pAKT (a, b, middle panels) and pS6 (c, d, top panels), and 
pGSK3 (c, d, middle panels). The α-Tubulin (α-Tub) antibody (a-d, bottom panels) was used for normalization (these results 
are characteristic of what we observed the three times these experiments performed). The numbers under the bands indicate 
the fold-induction or reduction, with respect to T = 0, and are normalized with respect to the α-Tubulin level. (e-j) Immunoflu-
orescence for β-III-Tubulin (red), phosphohistone-3 (PH3) (green) and Hoechst (blue) on E12.5 primary cortical cultures that 
were either not treated, treated with 50 ng/ml recombinant FGF8 or FGF15 for 24 and 48 hours (n = 4 for each experiment; p 
= 0.01, Student's t-test). (k) Graph showing the mitotic index calculated before starting the treatment (T0) and after 24 and 48 
hours of treatment with recombinant FGF8 and FGF15. Non-treated cells were used as a control. The mitotic index was calcu-
lated by dividing the number of PH3+ cells with the total number of cells (Hoechst labeled nuclei). Bars in the graph represent 
the standard deviation. The average number of nuclei and PH3+ cells for each sample/350 μm2 were as follow. T0: 113.5 ± 5 
nuclei and 6.25 ± 2.5 PH3+ cells. At 24 hours: control, 226.75 ± 4 nuclei and 20.5 ± 3.8 PH3+ cells; FGF8, 297.5 ± 12.5 nuclei 
and 48.3 ± 1.5 PH3+ cells; FGF15, 113 ± 10 nuclei and 8.25 ± 2.5 PH3+ cells. At 48 hours: control, 79.6 ± 3 nuclei and 8.25 ± 1 
PH3+ cells; FGF8, 164 ± 11 nuclei and 29 ± 3 PH3+ cells; FGF15, 44 ± 3 nuclei and 3.4 ± 0.5 PH3+ cells.Neural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
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unknown what induces expression of the earliest Fgf
(Fgf8) in the anterior neural ridge. However, Fgf8 is posi-
tively upstream of Fgf17 and Fgf18 (Additional file 1q-r')
[17], whereas it appears to repress Fgf15 in the rostral mid-
line (Figure 1c, d). In the Fgf8Null/Neosevere hypomorph,
Fgf15 expression remains strong, albeit in a reduced area
(Figure 1c, d), perhaps secondary to the reduced prolifer-
ation in this region [22]. On the other hand, induction/
maintenance of Fgf15 expression clearly depends on SHH
function (Additional file 2) [6,20,35], as does mainte-
nance of Fgf8 expression [68]. Fgf15 does not appear to
have a major role in regulating expression of Spry2, an
intracellular antagonist of FGF8 signaling (Figures 1g, j
and 6a–l). On the other hand, there is maybe a subtle
increase in Fgf8 expression in the Fgf15 mutant (Figure 1g,
h); a more quantitative analysis will be needed to verify
this observation. Thus, the rostral patterning center has
parallel signaling capabilities, one dominated by FGF8
and the other dominated by FGF15, which depends on
SHH and not FGF8 (see schema in Figure 8). Currently,
functions for FGF3 and FGF18 in the mammalian rostral
patterning center are not known, whereas FGF3 and FGF8
have redundant functions in zebrafish [67].
Patterning the rostroventral telencephalon: FGF15 and 
FGF8/17 are competing signals
FGF8 and FGF17 promote rostral telencephalic fate, in
part by repressing expression of CoupTF1, Fgfr3 and Emx2,
and promoting expression of Er81, Erm, Pea3, Mest and
Sp8 [12,17,21,22,24,25,41]. The dorsal patterning center,
through its expression of BMPs and Wnts [12,69], can, in
principle, repress the rostral patterning center. BMPs can
repress Fgf8 expression [68]; BMP and Wnt positively reg-
ulate Emx2 expression [70] and reduced Emx2 leads to
expansion of Fgf  expression [1,2,17,69]. However, cur-
rently, in vivo genetic studies have principally linked Wnt
signaling to hippocampal specification [1,2] and BMP sig-
naling to choroids plexus specification [71,72], so it
remains unclear to what extent the dorsal patterning
center participates in neocortical patterning.
Here we show that FGF15 functions, at least in part, to
repress rostral telencephalic fate, through promoting
CoupTF1 and repressing Mest and Sp8 (Figure 2). Thus,
FGF15, in conjunction with the putative role of the dorsal
patterning center, participates in repressing the size, and
perhaps the nature, of the rostral telencephalon.
FGF8 is also essential for inducing the ventral telen-
cephalon, through promoting expression of Nkx2.1 and
Shh [22,73]. While Fgf15 is expressed more ventrally than
Fgf8 within the rostral patterning center (septum) (this
paper) [17], to date we have detected only mild subpallial
or septal hypoplasia (Additional files 3 and 4; data not
shown). On the other hand, reduced Fgf19 expression in
zebrafish (homologue of mouse Fgf15), results in greatly
reduce expression of subcortical molecular markers [34],
perhaps suggesting divergent functions for these genes in
fish and mammals. In the mouse Fgf15 mutant, there are
reduced numbers of cortical GABAergic interneurons in
the dorsomedial cortex (Additional file 4); at this point we
can not distinguish whether this is a defect secondary to
the abnormal cortical environment, or secondary to
abnormal subpallial development (cortical interneurons
are generated in the basal ganglia anlage).
Where and when does FGF15 affect telencephalic 
development?
We propose that Fgf15 expression in the rostral patterning
center has a profound role in telencephalic patterning
during early neurulation based on the reduction of
CoupTF1 expression at E9.5 (Figure 1e, f). At this stage, the
distribution of Fgf15 mRNA is in a rostrocaudal gradient
whose pattern is roughly complementary to the expres-
sion of CoupTF1 mRNA (Figure 1a, c; Additional file 1a–
d). Assuming that the RNA and protein distributions are
similar at E9.5, then FGF15 secretion could promote
CoupTF1 expression in the most rostral domain. At later
stages,  Fgf15  expression in the septum and CoupTF1
Model of genetic interactions upstream and downstream of  Fgf15 and Fgf8 within embryonic telencephalon Figure 8
Model of genetic interactions upstream and down-
stream of Fgf15 and Fgf8 within embryonic telen-
cephalon. Shh promotes Fgf15 expression (Addition file 2) 
[6,20,35], and maintains Fgf8 expression [68]. Fgf8 is required 
for Shh induction [22]. Fgf15 activates, whereas Fgf8 
represses, expression of CoupTF1 (among other genes), 
which represses proliferation and promotes differentiation 
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expression in the cortex are far apart; therefore, it seems
unlikely that loss of Fgf15 from the septum at these stages
contributes to CoupTF1 reduction, especially in the dorso-
lateral cortex. However, Fgf15 is also expressed at the PSB,
and in the CGE (Additional file 1g–j); Fgf15 from those
sites could contribute to maintaining CoupTF1  cortical
expression at later developmental stages. This suggests
that FGF15 could play a key role in the putative patterning
center at the PSB. This is the first evidence for a role of a
secreted factor expressed in this putative patterning center
[7,8]. Fgf15 is also expressed in the lateral and medial gan-
glionic eminences (LGE/MGE) and the thalamus; cur-
rently, we have not detected phenotypes in these
structures.
Establishing the balance between proliferation and 
differentiation: distinct roles of FGF15(19) in fish and 
mammals
The most overt phenotype in the Fgf15  mutants was
reduced neurogenesis and increased proliferation in the
cortex (Figures 3 and 4). Consistent with this, in vitro cul-
tures of cortical progenitors with recombinant FGF15
have reduced neuronal proliferation (Figure 7). These
data differ from the results obtained by reducing expres-
sion of the zebrafish Fgf15 homologue (Fgf19) with anti-
sense oligonucleotides (morpholinos) [34]. Whereas
reduced Fgf19 expression led to a decrease in the number
of proliferating cells in the embryonic fish brain, Fgf15-/-
mice showed increased proliferation. These divergent
phenotypes could be explained by the different method-
ologies to reduce gene expression (constitutive deletion
mutation versus morpholino), different compensatory
responses, or distinct functions of mouse Fgf15  and
zebrafish Fgf19. It is conceivable that the Fgf15 deletion
produces an amino-terminal fragment with altered signal-
ing properties; however, the deletion does remove exon 3,
which encodes the residues predicted to bind heparin sul-
fate proteoglycans and FGF receptors [32]. Future studies
with a Fgf19 zebrafish mutant will help resolve whether
zebrafish Fgf19 and mouse Fgf15 indeed have divergent
functions that may contribute to the divergent morpho-
genesis of the fish and mammalian telencephalons.
Opposite roles of FGF15 and FGF8 in regulating the 
balance between proliferation and differentiation through 
controlling CoupTF1 levels
We suggest that an important aspect of Fgf15's functions
is to promote expression of the CoupTF1 transcription fac-
tor, because the cortical phenotypes observed through
changing Fgf15's expression levels mirror those observed
when altering CoupTF1  dosage. Increased CoupTF1
represses proliferation and promotes neurogenesis,
whereas loss of CoupTF1  promotes proliferation and
represses neurogenesis [38]. As loss of Fgf15 expression
results in decreased CoupTF1 expression as early as E9.5
(Figure 1), we suggest that the Fgf15 mutant phenotype is
caused, in part, by reduced CoupTF1  levels. However,
because the neurogenesis phenotype in Fgf15 mutants is
more severe than that of the CoupTF1 mutants, other fac-
tors must contribute.
Unlike FGF15, FGF8 represses CoupTF1 [21,22]. Further-
more, FGF8 promotes proliferation in the developing tel-
encephalon [22] (Figure 7), as does FGF2 [14,60,74,75].
Thus, while the in vivo functions of certain FGFs (FGF2
and FGF8) promote proliferation in the developing telen-
cephalon, FGF15 has the opposite role. Therefore, FGF15
and FGF8 provide opposing signals from the rostral pat-
terning center that control the balance of proliferation
and differentiation. One can imagine how differential
modulation of these signals during development, disease,
or evolution will have profound effects on cortical size,
thickness and regional fate.
Interplay between FGF15 and FGF8/17 signaling: 
complementary effects on Spry and Fgf receptor 
expression
FGF15 and FGF8/17 are believed to signal through several
receptor tyrosine kinases (FGFR1-4) that are negatively
modulated by several mechanisms. Spry1-4 encode FGF-
induced cytoplasmic repressor of FGF-signaling [53,76].
While  Spry  expression is clearly reduced in the Fgf8
mutant forebrain [17,22], we did not detect a reduction in
Spry expression in the rostral patterning center/septum of
the Fgf15 mutants (Figures 1i, j and 6e–l). Fgfr3 appears to
have atypical signaling outputs. In fact, Fgfr3 mutant mice
have increased proliferation and reduced differentiation
of chondrocytes [77,78], and pancreatic cells [79]. Fgf8
mutants have increased Fgfr3 expression [21], whereas the
Fgf15 mutants show the opposite phenotype (Figure 6).
Thus, we propose that FGF15 is a secreted modulator of
several cellular processes that are promoted by FGF8.
Distinct effects of FGF15 and FGF8 on signalling pathways
Towards elucidating the differential effects of reducing
FGF15 and FGF8, we compared the effects of recombinant
FGF15/19 and FGF8 on the levels of phosphorylated
forms of ERK (42/44), AKT, S6 and GSK3 in primary cul-
tures made from E12.5 mouse cortex (Figure 7). We dem-
onstrated that while FGF15 phosphorylation of ERK
kinase (42/44) was transient (approximately 15 minutes),
FGF8 phosphorylation of ERK was sustained over the time
of the experiment (1 hour). The duration of FGF-signaling
is associated with distinct cellular responses [80]. For
example, in fibroblasts, sustained activation of ERK corre-
lates with S phase entry [81-84], while in PC12 cells, sus-
tained, but not transient, activation of ERK induces
differentiation into sympathetic-like neurons [85-88].Neural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
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FGF15 and FGF8 also had distinct effects on the levels of
pAKT and pS6. While FGF8 increased the levels of both
pAKT and pS6 phosphorylation, FGF15 did not increase
pAKT, and appeared to reduce pS6. The differences
observed in the phosphorylation of the effector kinases of
the FGF signaling pathway may contribute to the opposite
phenotype of the FGF15 and FGF8 mutants observed in
vivo and in vitro.
The simplest model to account for the signaling differ-
ences between FGF8 and FGF15 would be that they differ-
entially activate/repress FGF, or other, receptors. While
studies have established the effects of distinct ligands and
receptor combinations on mitogenesis and in vitro bind-
ing [14,55,57,89], definitive elucidation of the in vivo bio-
chemistry is lacking, particularly for FGF15. Although
FGF15/19 preferentially binds FGFR4 [33,55-57], this
receptor does not appear to be expressed in the forebrain
until approximately E14.5 (Additional file 6). In addition,
FGF15/19 binds Klotho-β, which acts as a co-receptor. We
have not observed any expression of Klotho-β in the fore-
brain at E12.5 and E14.5 (data not shown). Therefore, it
is likely that FGF15 functions by regulating other FGF
receptors. Therefore, additional analysis is needed to
establish how FGF8 and FGF15 signal to elucidate how
they differentially regulate the balance between prolifera-
tion and differentiation.
Conclusion
We provide novel evidence that FGF15 and FGF8 have
opposite functions in mouse forebrain development. In
the cortex, FGF15 suppresses proliferation and promotes
differentiation, expression of CoupTF1 and caudoventral
fate. Furthermore, using primary cultures and recom-
binant proteins, we demonstrate that FGF15 and FGF8
differentially phosphorylate ERK (p42/44), AKT and S6.




The Fgf15-/- [32], Fgf8Null/+ and Fgf8Neo/+ [22], Shh± [90],
BAT-gal [52] and RARE-LacZ [47] strains were maintained
on a mixed C57BL6/CD1 genetic background. Screening
of the mutant alleles was performed by PCR genotyping as
described previously [22,32,90]. Noon on the day of the
vaginal plug was considered as E0.5. Mouse colonies were
maintained at the University of California, San Francisco,
in accordance with National Institutes of Health and
UCSF guidelines.
Histology
Pregnant females were deeply anesthetized with CO2 and
sacrificed by cervical dislocation. The embryos were dis-
sected and the brains were fixed by immersion in 4% para-
formaldehyde in phosphate buffered saline. The tissue
was cryoprotected by immersion in 30% sucrose/phos-
phate buffered saline, embedded in OCT (Tissue-Tek,
Sakura Finetek, Torrance, CA, USA), and cryostat sec-
tioned (10–20 μm).
Immunofluorescence on cryostat sections was performed
as previously described [22]. The antibodies used were as
follows: mouse anti-Tuj1 (1:1,000; Covance, Princeton,
NJ, USA), rabbit anti-PH3 (1:200; Upstate/Millipore, Bill-
erica, MA, USA), mouse anti-BrdU (1:100; Becton Dickin-
son, Franklin Lakes, NJ, USA), rat anti-BrdU (1:100;
Abcam, Cambridge, MA, USA). Goat anti-rabbit, goat
anti-mouse and goat anti-rat secondary antibodies, conju-
gated with either Alexa 488 or Alexa 594 (1:300, Molecu-
lar Probes/Invitrogen, Carlsbad, CA, USA), were used at a
dilution of 1:300.
In situ RNA hybridization on cryostat sections was per-
formed as previously described [22]. Comparison of gene
expression changes between brains of different genotypes
was performed by matching the planes of section to the
best of our abilities, using multiple anatomical features.
Whenever possible, this was performed for multiple
planes of section for each gene, and from at least two
brains for each genotype.
Cell cycle analysis
For the cell cycle kinetic analysis, a single injection of IdU
(50 μg/g; Sigma, St Louis, MO, USA) was administered to
pregnant females, carrying either E12.5 or E14.5 embryos,
at T = 0. This was followed at T = 1.5 hours by a single
injection of BrdU (50 μg/g; Sigma). Mice were sacrificed at
T = 2 hours.
For the quantification of the numbers of cells exiting the
cell cycle (Q fraction), IdU was administered as a single
injection at T = 0. This was followed at T = 1.5 hours by
sequential injections of BrdU every 3 hours, for a total of
15 hours. Mice were sacrificed at 0.5 hours after the last
injection.
For the calculation of BrdU/IdU labeling index, we sam-
pled two 100 μm bins spaced 200 μm apart in the ventro-
lateral region of the cortex (rectangles in Figure 4 and
Additional file 5). Images were acquired using a confocal
microscope (Radiance 2000, Bio-Rad, Hercules, CA, USA)
with a 20× or a 40× objective. BrdU/IdU positive cells (red
channel) and BrdU positive cells (red channel) were
counted together with the total number of cells for each
bin (calculated by the number of Hoechst labeled nuclei).
The experimenter was blind during sampling, image anal-
ysis, data collection and statistical analysis. Digitized
images were imported into Phostoshop CS3 (Adobe) for
counting. Statistical analysis was performed with SPSSNeural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
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(SPSS) and data plotted using Excel (Microsoft) and the
significance level was taken as p < 0.05.
A total of three cases were counted in sections spaced
evenly through the rostrocaudal cortex. The cell cycle
length was calculated using the paradigm described in
[91].
FGF15 adenovirus preparation and FGF15 protein 
purification
The adenovirus containing the Fgf15 coding region with a
(His)6 tag was the gift of Dr Steven Kliewer (UT South-
western Medical Center, Dallas, TX, USA). The FGF15 ade-
novirus was grown in HEK293 cells (ATCC: CRL 1573)
and titrated onto the same cells. 1.2 × 107 COS7 cells
(ATCC: CRL 1673) were plated in T150 flasks (6 flasks for
each protein preparation). The cells were infected with
adenovirus at a multiplicity of infection of 2 for 2 hours
in Dulbecco's modified Eagle's medium (DMEM)/2%
fetal calf serum. After the infection, the medium was
changed with DMEM without fetal calf serum. Three days
post-infection the supernatant was collected, equilibrated
with a 10× solution of 500 mM Tris/HCl pH8, 1 M NaCl,
100 mM Imidazole, centrifuged 20 minutes at 10,000 g,
and passed through a 0.8 ml nickel agarose column (Ni-
NTA Agarose, Quiagen, Valencia, CA, USA). The column
was washed with 25 column volumes of 50 mM Tris/HCl
pH 8, 0.25 M NaCl, 0.1% NP-40, 10 mM Imidazole, and
then with 25 column volumes of 20 mM Tris/HCl pH 8,
0.25 M NaCl, 10 mM Imidazole. The His-tagged FGF15
protein was eluted in 20 mM Tris/HCl pH 8, 0.25 M NaCl,
0.5 M Imidazole. The eluate was passed through a PD
MidiTrap G-25 desalting column (GE Healthcare, Piscata-
way, NJ, USA) following the manufacturer's protocol,
eluted in 10 mM Tris/HCl pH 7.5, 135 mM NaCl, 5 mM
KCl, 1 mM MgCl2, and finally concentrated with the Ami-
con Ultra-4 3 k centrifugal filter device (Millipore, Biller-
ica, MA, USA). The purity of the protein preparation was
assessed by Coomassie Blue staining and by immunoblot-
ting (western blot) using an anti-FGF15 polyclonal anti-
body (SC 16816, Santa Cruz Biotechnology, Santa Cruz,
CA, USA).
Primary cell culture and treatment with recombinant FGFs
Wild-type CD1 brains (E12.5) were used to prepare pri-
mary cortical cultures. The brains were removed in ice-
cold Hank's solution (HBSS; Invitrogen, Carlsbad, CA,
USA), and the cortices dissected, after removing the exter-
nal membranes. The samples were mechanically dissoci-
ated in DMEM/10% fetal bovine serum (FBS; Invitrogen)
and the single cell suspensions were plated at a density of
2.5 × 105 cells per cm2 in two-well chamber slide (Lab-Tek,
Nalgene, Rochester, NY, USA). We were careful to plate
the cells at the same density in all of the wells. After 16
hours the medium was replaced with DMEM/5% FBS and
finally changed with DMEM/0.5% FBS after 24 hours. The
cells were starved in DMEM/0.5% FBS for 24 hours before
the treatment with the recombinant proteins. The mouse
FGF15 recombinant protein was added to the cells at a
concentration of 50 ng/ml in DMEM/0.5% FBS/5 μg/ml
Heparin. This protein concentration corresponds to 1.7
pmol/ml for FGF2 and 2 pmol/ml for FGF15 and FGF8.
The same protocol was used for human FGF2, FGF8 and
FGF19 recombinant proteins (Fitzgerald Industries Inter-
national, RDI, Concord, MA, USA).
For counting the cultured cells, we used an unbiased
method that gave every cell an equal chance of being sam-
pled. We defined a systematic series of fields of view in the
culture area to cover the surface of the well. The experi-
menter was blind to sample identity during sampling,
image analysis, data collection and statistical analysis.
Images were acquired on a fluorescence microscope with
a 20× objective. We sampled at least two different wells
for each time point obtained from four independent
experiments. Digitized images were imported into Phos-
toshop CS3 (Adobe) for counting. Statistical analysis was
performed with SPSS (SPSS) and data plotted using Excel
(Microsoft) and the significance level was taken as p <
0.05.
Immunoblotting
Cells from primary E12.5 cortical cultures were lysed in
radioimmunoprecipitation buffer (RIPA: 50 mM Tris/HCl
pH 7.5, 150 mM NaCl, 0.5% sodium deoxycolate, 0.1%
SDS, 1% NP-40) supplemented with protease inhibitors
(Protease Inhibitor Cocktail, Roche, Indianapolis, IN,
USA) and phosphatase inhibitors (Phosphatase Inhibitor
Mix 1 and 2, Sigma). Protein samples (10 μg each) were
resolved on polyacrylamide gels and transferred to nitro-
cellulose membranes by electroblotting. Membranes were
pre-incubated in 5% nonfat dry milk in Tris buffered solu-
tion (TBS)/0.1% Tween-20 (TBST) and then incubated O/
N with the primary antibodies in TBST/5% bovine serum
albumin in TBST. The primary antibodies were: rabbit-
anti phospho-p44/42 (Thr202/Tyr204) MAPK (1:1,000;
Cell Signaling, Boston, MA, USA), rabbit anti-phospho-
Akt (Ser 473) (1:500; Cell Signaling), rabbit anti-phos-
pho-GSK3α/β (Ser 21/9) (1:1,000; Cell Signaling), rabbit
anti-phospho-S6 ribosomal protein (Ser235/236)
(1:1,000; Cell Signaling), and mouse anti-α-tubulin
(1:10,000; Sigma). Membranes were probed with the
appropriate goat horseradish peroxidase-conjugated anti-
bodies (1:500; Biorad, Hercules, CA, USA) and developed
using ECL reagents (GE Healthcare). Each experiment was
repeated at least three times. Quantification of optical
density was done using NIH ImageJ software; the intensity
of the bands was normalized with respect to the intensity
of the α-Tubulin band. The numbers indicated in Figure 7Neural Development 2008, 3:17 http://www.neuraldevelopment.com/content/3/1/17
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and Additional file 7 represent the fold-induction, or
reduction, from the time point before FGF addition (T0).
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Additional file 1
Fgf15 and Fgf17 expression in Fgf8Null/Neo mutants and Fgf17 expression 
in Fgf15-/- mutants. (a-p') In situ hybridization of Fgf15 in Fgf8Null/Neo 
embryos. E9.5: wild type (a-d); mutant (a'-d'); (a"-d", a"'-d"') show 
higher magnification images; horizontal sections. E12.5: wild type (e-j); 
mutant (e'-j'); coronal sections. E14.5: wild type (k-p); mutant (k'-p'); 
coronal sections. (q-r') In situ hybridization of Fgf17 in Fgf8Null/Neo 
embryos at E12.5: wild type (q, r); mutant (q', r'); coronal sections. (s-
t') In situ hybridization of Fgf17 in Fgf15-/-embryos. E14.5: wild type (s, 
t); mutant (s', t'); coronal sections. Bar in (a, e, k) is 200 μm.




Fgf15 and the SHH pathway. (a-p') Analysis of Fgf15 expression in the 
Shh mutant. E12.5: Shh± (a-o); Shh-/- mutant (a'-o'); coronal sections. 
E14.5: Shh± (b-p); Shh-/- mutant (b'-p'); coronal sections. (q-r') Expres-
sion of SHH downstream effector Gli3 in the Fgf15 mutants in coronal 
sections at E12.5 (q wild type, q' Fgf15-/-mutant) and E14.5 (r wild type, 
r' Fgf15-/- mutant). Bar in (a) and (b) is 200 μm.




Fgf15 mutant embryos morphology. The morphology of Fgf15-/- mutant 
embryos was compared to the wild type. (a, b) Examples of lateral views 
of Fgf15 mutant and wild-type embryos at E10.5. -(c, d) Comparison of 
dorsal views of Fgf15 mutant and wild-type dissected brains at E14.5. (e, 
f) β-III-Tubulin immunostaining on coronal hemisections of E14.5 
brains.




Analysis of markers of the basal ganglia and basal ganglia-derived cortical 
interneurons in the Fgf15 mutants. (a-j) In situ hybridization on coronal 
sections at E14.5: Gad67 (a-d), Reelin (e, f), Nkx2.1 (g, h), Pax6 (i, 
j). Ncx, neocortex; Pcx, piriform cortex; Se, septum; St, striatum. Arrows 
in (a, b) indicate reduced cortical interneurons in the dorsomedial cortex; 
arrowheads in (a, b) indicate suggestive evidence for increased Gad67 
expression in the deep tangential migration. Arrows in (c, d) show 
reduced thickness in the mantle zone of the ventral septum and piriform 
cortex. Bar in (a, c) is 200 μm.




Analysis of proliferation and cell cycle in the Fgf15 mutants. (a-c) The 
number of progenitors undergoing mitosis at E12.5 was determined by 
PH3 immunofluorescence (n = 3; p = 0.0024, Student's t-test). (d-f) the 
analysis of the cell cycle length was performed at E12.5 by double labeling 
with IdU and BrdU.




Analysis of FGF signaling components in the Fgf15 mutants. In situ 
hybridization on coronal sections. (a-d') Fgfr1 at E12.5 (a, b), and at 
E14.5 (c, d); (c', d') show higher magnification images. (e-h') Fgfr2 at 
E12.5 (e, f), and at E14.5 (g, h); (g', h') show higher magnification 
images. (i-l) Fgfr3 at E12.5 (i, j), and at E14.5 (k, l)). (m-n) Fgfr4 at 
E14.5. CP: cortical plate. Bar in (a) is 200 μm.
Click here for file
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